Clinical Characteristics and Pathologic Profiles Correlation of Primary Lung Cancer: A 6-Year Retrospective Study in Thailand’s Metropolitan Medical Center
Article Sidebar
Main Article Content
Abstract
Background: Since 2018, the global incidence of lung cancer had increased to 2.1 million causing lung cancer to be a major leading cause of cancer-related mortality in worldwide, with 29 percent mortality rate. This is causing by an increasing tobacco consumption rate, especially in developing countries. For other risk factors that associate with lung cancer were sex, age and metropolitan people.
Aim: To study clinical characteristics and pathologic profiles correlation of primary lung cancer in Thailand’s metropolitan medical center
Method: A retrospective study in Vajira hospital. The study population with diagnosed with primary lung cancer between January 2016, and May 2021. The information was collected: sex, age, pathologic profile, and stage.
Results: A total of 110 primary lung cancer patients were found at Vajira Hospital from January 2013 to June 2021, consisting of 52 males (47.3%) and 58 females (52.7%). The mean age for patients at the time of diagnosis was 62.93 years. Most common histologic type of lung cancer in both metropolitan and non-metropolitan residents were invasive adenocarcinoma (81.8% in total) with 41.8% and 40%, respectively. Most presentation of lung cancer staging were diagnosed at early stage.
Conclusions: This study revealed a growing incidence of adenocarcinoma, an increasing rate of female cases in both metropolitan and non-metropolitan nonsmoker female patients. However, further studies on risk factors of primary lung cancers emphasis on nonsmoker women are recommended.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. Global Health Estimates 2021: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2020. Geneva: World Health Organization; 2021.
World Health Organization. Noncommunicable diseases country profiles 2018. Geneva: World Health Organization; 2018.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424.
Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med 2016;4(8):150. doi: 10.21037/atm.2016.03.11.
O'Neil ME, Henley SJ, Rohan EA, Ellington TD, Gallaway MS. Lung Cancer Incidence in Nonmetropolitan and Metropolitan Counties - United States, 2007-2016. MMWR Morb Mortal Wkly Rep 2019;68(44):993-8.
Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D. Cancer Epidemiology and Prevention. Oxford University Press; 2017.
Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M, McAfee TA. Lung cancer incidence trends among men and women--United States, 2005-2009. MMWR Morb Mortal Wkly Rep 2014;63: 1–5.
Henley SJ, Anderson RN, Thomas CC, Massetti GM, Peaker B, Richardson LC. Invasive Cancer Incidence, 2004-2013, and Deaths, 2006-2015, in Nonmetropolitan and Metropolitan Counties - United States. MMWR Surveill Summ 2017;66(14):1-13.
TKhuhaprema T, Sriplung H, Sangrajrang S. Cancer in Thailand vol.VII, 2007- 2009. Bangkok: MINISTRY OF PUBLIC HEALTH; 2013.
Lee P, Forey B. Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review. BMC Cancer 2013; 13: 189. doi: 10.1186/1471-2407-13-189.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47.
Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015;7(283):283ra53. doi: 10.1126/scitranslmed.aaa7161.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2(8):706-14.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 ;348(6230):124-8
Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol 2016 ;11(10):1653-71.
Mowls DS, Campbell J, Beebe LA. Race and Gender Disparities in Lung Cancer Incidence Rates, 2001-2010. J Okla State Med Assoc 2015;108(11):482–7.
Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008 ;3(8):819-31.
Debieuvre D, Oster J-P, Riou R, Berruchon J, Levy A, Mathieu J-P, et al. The new face of non-smallcell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart. Lung Cancer 2016;91:1–6.
Schwartz AG, Cote ML. Epidemiology of Lung Cancer. Adv Exp Med Biol 2016; 893 :21–41.
Denton EJ, Hart D, Wainer Z, Wright G, Russell PA, Conron M. Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre. Intern Med J 2016; 46(8): 946–54.
Kontakiotis T, Manolakoglou N, Zoglopitis F, Iakovidis D, Sacas L, Papagiannis A, et al. Epidemiologic trends in lung cancerover two decades in Northern Greece:an analysis of bronchoscopic data. Monaldi Arch Chest Dis 2009;71(4):147-52.
Scagliotti G V, Longo M, Novello S. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 2009; 21(2): 99–104.
Toh CK, Wong EH, Lim WT, Leong SS, Fong KW, Wee J, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 2004;126(6):1750-6.
Ha SY, Choi S-J, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget 2015; 6(7):5465–74.
Aungkulanon S, Pitayarangsarit S, Bundhamcharoen K, Akaleephan C, Chongsuvivatwong V, Phoncharoen R, et al. Smoking prevalence and attributable deaths in Thailand: Predicting outcomes of different tobacco control interventions. BMC Public Health 2019; 19: 984. doi:10.1186/s12889-019-7332-x
Novaes FT, Cataneo DC, Ruiz Junior RL, Defaveri J, Michelin OC, Cataneo AJM. Câncer de pulmão: histologia, estádio, tratamento e sobrevida. J Bras Pneumol 2008; 34(8) :595–600.
McWilliam A, Vasquez Osorio E, Faivre-Finn C, van Herk M. Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 2019; 137: 71–6.
Jørgensen N, Meline EL, Jeppesen SS, Hansen O, Nielsen M, Schytte T. The effect of tumor laterality on survival for non-small cell lung cancer patients treated with radiotherapy. Acta Oncol 2019; 58(10): 1393–8.
Shimizu K, Yoshida J, Nagai K, Nishimura M, Ishii G, Morishita Y, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130: 160–5.
Tao H, Hayashi T, Sano F, Takahagi A, Tanaka T, Matsuda E, et al. Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller. J Surg Res 2013; 185: 250–4.
Kadota K, Nitadori JI, Sima CS, Ujiie H, Rizk NP, Jones DR, et al. Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol 2015;10(5):806-14.
Jia M, Yu S, Yu J, Li Y, Gao H, Sun PL. Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system. BMC Cancer 2020; 20: 705. doi: 10.1186/s12885-020-07200-w.
Jia M, Yu S, Gao H, Sun P-L. Spread Through Air Spaces (STAS) in Lung Cancer: A MultiplePerspective and Update Review. Cancer Manag Res 2020; 12: 2743–52.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124-8. doi: 10.1126/science.aaa1348.
Califano R, Abidin A, Tariq NU, Economopoulou P, Metro G, Mountzios G. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat Rev 2015;41(5):401-11. doi: 10.1016/j.ctrv.2015.03.009